We could not find any results for:
Make sure your spelling is correct or try broadening your search.
VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed ... VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy. Show more
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech PR Newswire HENDERSON, Nev., April 23, 2024 HENDERSON, Nev., April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE...
U.S. index futures are showing an uptrend in pre-market trading this Tuesday, with investors keen on driving a recovery that had previously lifted stocks to their all-time highs, looking to...
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update PR Newswire HENDERSON, Nev., March 25, 2024 Conference call to discuss financial and operational results...
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update PR Newswire HENDERSON, Nev., March 21, 2024 Conference call to take place on Tuesday...
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan PR Newswire HENDERSON, Nev., March 20, 2024 HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE...
Volition appoints Dr Andrew Retter as Chief Medical Officer PR Newswire HENDERSON, Nev., March 19, 2024 HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX...
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar PR Newswire HENDERSON, Nev., Feb. 2, 2024 HENDERSON, Nev., Feb. 2, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.29 | 46.0317460317 | 0.63 | 1.02 | 0.57 | 913283 | 0.83511397 | CS |
4 | 0.1591 | 20.9094493363 | 0.7609 | 1.02 | 0.57 | 318716 | 0.79783393 | CS |
12 | -0.11 | -10.6796116505 | 1.03 | 1.23 | 0.57 | 189089 | 0.84961216 | CS |
26 | 0.1099 | 13.5662263918 | 0.8101 | 1.23 | 0.55 | 205221 | 0.85841792 | CS |
52 | -0.67 | -42.1383647799 | 1.59 | 2.1 | 0.55 | 185749 | 1.02898152 | CS |
156 | -2.43 | -72.5373134328 | 3.35 | 4.1401 | 0.55 | 143128 | 1.96444057 | CS |
260 | -2.48 | -72.9411764706 | 3.4 | 7.69 | 0.55 | 188059 | 3.08636342 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions